Long term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall A case report

被引:7
作者
Gui, Xinyu [1 ]
Li, Huiping [1 ]
Song, Guohong [1 ]
Shao, Bin [1 ]
Jiang, Hanfang [1 ]
机构
[1] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing,Dept Breast Oncol, Beijing, Peoples R China
关键词
bevacizumab; breast cancer; chest wall metastasis; triple negative; CONTAINING THERAPY; ANGIOGENESIS; METASTASIS; RECEPTORS;
D O I
10.1097/MD.0000000000013410
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: Triple-negative breast cancer (TNBC) is associated with unfavorable prognosis due to lack of targeted agents. Bevacizumab, an anti-angiogenic monoclonal antibody against vascular endothelial growth factor A, has shown clinical effects in patients with TNBC. Patient concerns: We reported a 49-year-old woman presenting with a giant breast tumor. Diagnoses: Stage IV TNBC with chest wall metastasis. Interventions: The patient underwent long-term use of bevacizumab combined with chemotherapy. Outcomes: The patient was on follow-up for 46 months, a remarkable improvement of the chest wall cutaneous lesion was observed. Lessons: Bevacizumab may provide benefits for TNBC patients with chest wall metastasis.
引用
收藏
页数:3
相关论文
共 17 条
  • [1] Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry
    Bauer, Katrina R.
    Brown, Monica
    Cress, Rosemary D.
    Parise, Carol A.
    Caggiano, Vincent
    [J]. CANCER, 2007, 109 (09) : 1721 - 1728
  • [2] Androgen receptors: A marker to increase sensitivity for identifying breast cancer in skin metastasis of unknown primary site
    Bayer-Garner, IB
    Smoller, B
    [J]. MODERN PATHOLOGY, 2000, 13 (02) : 119 - 122
  • [3] Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
    Bell, R.
    Brown, J.
    Parmar, M.
    Toi, M.
    Suter, T.
    Steger, G. G.
    Pivot, X.
    Mackey, J.
    Jackisch, C.
    Dent, R.
    Hall, P.
    Xu, N.
    Morales, L.
    Provencher, L.
    Hegg, R.
    Vanlemmens, L.
    Kirsch, A.
    Schneeweiss, A.
    Masuda, N.
    Overkamp, F.
    Cameron, D.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (04) : 754 - 760
  • [4] Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial
    Brufsky, Adam
    Valero, Vicente
    Tiangco, Beatrice
    Dakhil, Shaker
    Brize, Arija
    Rugo, Hope S.
    Rivera, Ragene
    Duenne, Anja
    Bousfoul, Naima
    Yardley, Denise A.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (03) : 1067 - 1075
  • [5] Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A
    Choi, Sul Ki
    Kim, Hoe Suk
    Jin, Tiefeng
    Hwang, Eun Hye
    Jung, Minji
    Moon, Woo Kyung
    [J]. BMC CANCER, 2016, 16
  • [6] Huiping L, 2015, ONCOL PROG, V13, P609
  • [7] Metastatic Behavior of Breast Cancer Subtypes
    Kennecke, Hagen
    Yerushalmi, Rinat
    Woods, Ryan
    Cheang, Maggie Chon U.
    Voduc, David
    Speers, Caroline H.
    Nielsen, Torsten O.
    Gelmon, Karen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) : 3271 - 3277
  • [8] Cutaneous metastasis: A meta-analysis of data
    Krathen, RA
    Orengo, IF
    Rosen, T
    [J]. SOUTHERN MEDICAL JOURNAL, 2003, 96 (02) : 164 - 167
  • [9] Efficacy and Safety of Bevacizumab Combined with Chemotherapy for Managing Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
    Li, Qin
    Yan, Han
    Zhao, Pengfei
    Yang, Yifan
    Cao, Bangwei
    [J]. SCIENTIFIC REPORTS, 2015, 5
  • [10] Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
    Linderholm, B. K.
    Hellborg, H.
    Johansson, U.
    Elmberger, G.
    Skoog, L.
    Lehtio, J.
    Lewensohn, R.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 (10) : 1639 - 1646